calcitonin and Spinal-Diseases

calcitonin has been researched along with Spinal-Diseases* in 1 studies

Other Studies

1 other study(ies) available for calcitonin and Spinal-Diseases

Article	Year
Successful treatment of low turnover osteoporosis resulting from prolonged reserpine therapy with intermittent calcitonin and phosphate therapy. Calcified tissue international, 1992, Volume: 51, Issue:4 Coherence therapy, popularly known by the acronym ADFR (Activate, Depress, Free, Repeat), was designed to increase bone mass in osteopenic patients. Accordingly, we report a case of a hypogonadal male with histologically proven low bone turnover osteoporosis and a progressive vertebral fracture syndrome, who responded favorably to ADFR treatment with the use of salmon calcitonin and inorganic phosphate. Dramatic increments in bone mass were observed during a 68-month period of therapy. Serial quantitative computerized tomography demonstrated a 146% increase from baseline in bone mineral density for the first 30 months of treatment, and dual energy radiography yielded a 36.5% increase for the subsequent 31-68 months. Furthermore, no episode of fracture occurred since coherence therapy was initiated. Topics: Adult; Bone Density; Calcitonin; Drug Therapy, Combination; Humans; Male; Osteoporosis; Phosphates; Reserpine; Spinal Diseases	1992

Article

Year

Successful treatment of low turnover osteoporosis resulting from prolonged reserpine therapy with intermittent calcitonin and phosphate therapy.

Calcified tissue international, 1992, Volume: 51, Issue:4

Coherence therapy, popularly known by the acronym ADFR (Activate, Depress, Free, Repeat), was designed to increase bone mass in osteopenic patients. Accordingly, we report a case of a hypogonadal male with histologically proven low bone turnover osteoporosis and a progressive vertebral fracture syndrome, who responded favorably to ADFR treatment with the use of salmon calcitonin and inorganic phosphate. Dramatic increments in bone mass were observed during a 68-month period of therapy. Serial quantitative computerized tomography demonstrated a 146% increase from baseline in bone mineral density for the first 30 months of treatment, and dual energy radiography yielded a 36.5% increase for the subsequent 31-68 months. Furthermore, no episode of fracture occurred since coherence therapy was initiated.

Topics: Adult; Bone Density; Calcitonin; Drug Therapy, Combination; Humans; Male; Osteoporosis; Phosphates; Reserpine; Spinal Diseases

1992